Economic Burden of Hospitalizations Related To Pulmonary Arterial Hypertension (PAH) In France
نویسندگان
چکیده
منابع مشابه
The economic burden of pulmonary arterial hypertension (PAH) in the US on payers and patients
BACKGROUND Pulmonary arterial hypertension (PAH) is a rare condition that can ultimately lead to right heart failure and death. In this study we estimated the health care costs and resource utilization associated with PAH in a large US managed care health plan. METHODS Subjects with claims-based evidence of PAH from 1/1/2004 to 6/30/2010 (identification period) were selected. To be included i...
متن کاملPulmonary Arterial Hypertension (PAH) Panel
The PAH Panel provides a high quality read-out of all genes with well-established association to pulmonary arterial hypertension. Our OS-SeqTM technology provides high coverage clinical grade sequencing and enables reliable diagnostics for PAH patients with significantly lower costs and faster turnaround time (basic service TAT 21 days and Express service TAT 7-10 days). The PAH Panel has under...
متن کاملSystematic Review of Economic Evaluation of Drug Treatments in Pulmonary Arterial Hypertension (PAH)
Pulmonary arterial hypertension (PAH) is a rare disease but PAH treatment cost is very high. Nowadays, there has been no cost-effectiveness information related to PAH treatments in Thailand. The aim of this study was to systematically review economic evaluation studies of drugs treatment in PAH. Studies reporting in term of clinical outcomes and costs during January 1990 to October 2012 were se...
متن کاملRiociguat dose titration in patients with chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH)
Clinical background Despite recent advances, the prognosis for patients with pulmonary hypertension remains poor. Riociguat (BAY 63-2521) is a novel oral stimulator of the nitric oxide (NO) receptor soluble guanylate cyclase, and synergizes with low levels of bioavailable NO. Its safety and efficacy in dose titration were studied in patients with PAH (n = 33) or CTEPH (n = 42) in this multicent...
متن کاملTHE EFFECTS OF CAPTOPRIL ON PULMONARY AND SYS TEMIC ARTERIAL PRESSURES IN HIGHALTITUDE PULMONARY HYPERTENSION
The purpose of this investigation was to assess the effect of captopril on both systemic (P.a) and pulmonary arterial pressures (PPA) in patients with high-altitude pulmonary hypertension (HAPH). Seventeen patients (mean age 44±6.8 years) with HAPH and mild to moderate systemic arterial hypertension were included in the study. All patients underwent right heart catheterization with measurem...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2017
ISSN: 1098-3015
DOI: 10.1016/j.jval.2017.08.1199